Decreased E-Cadherin levels in ILC BC-PDMs are in accordance with inactivating CDH1 (E-Cadherin) mutations that are frequently observed in ILC tumors and disrupt cellular adhesion/epithelial integrity [70, 71]. The gene discussed is CDH1; the disease is breast cancer.